Key facts
- Caligan Partners LP filed SCHEDULE 13G for Opus Genetics, Inc. Common Stock, $0.0001 par value per share (IRD).
- Disclosed ownership: 8.5%.
- Date of event: 31 Mar 2026.
Caligan Partners LP - 31 Mar 2026 SCHEDULE 13G Report for Opus Genetics, Inc. Common Stock, $0.0001 par value per share (IRD)
- Filing Manager
- Caligan Partners LP
- Reporting Manager
- Caligan Partners LP
- Symbol
- IRD
- Shares outstanding
- 71,470,918 shares
- Disclosed Ownership
- 6,075,028 shares
- Ownership
- 8.5%
- Form type
- SCHEDULE 13G
- Filing time
- 15 May 2026, 10:56:23 UTC
- Date of event
- 31 Mar 2026
- SEC
- View on sec.gov
Key filing fact
Caligan Partners LP disclosed 8.5% ownership in Opus Genetics, Inc. Common Stock, $0.0001 par value per share (IRD) on 31 Mar 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2026, 10:56.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Caligan Partners LP | 8.5% | 6,075,028 | 0 | 6,075,028 | /s/ David Johnson | David Johnson, Managing Partner | |
| JOHNSON DAVID EDWARD | 8.5% | 6,075,028 | 0 | 6,075,028 | /s/ David Johnson | David Johnson, Individually |
CIK / CUSIP context first